scholarly journals Effectiveness of a Multifaceted Educational Intervention to Enhance Therapeutic Regimen Adherence and Quality of Life Amongst Iranian Hemodialysis Patients: A Randomized Controlled Trial (MEITRA Study)

2020 ◽  
Vol Volume 13 ◽  
pp. 361-372 ◽  
Author(s):  
Leila Zhianfar ◽  
Haidar Nadrian ◽  
Mohammad Asghari Jafarabadi ◽  
Fatemeh Espahbodi ◽  
Abdolreza Shaghaghi
2016 ◽  
Vol 33 (S1) ◽  
pp. S436-S436
Author(s):  
A.A. Hasan

BackgroundPsycho-educational interventions for people diagnosed with schizophrenia (PDwS) and their primary caregivers (PC) can improve knowledge about schizophrenia, reduce PCs’ burden of care, PDwSs’ symptoms, and enhance PCs’ quality of life. However, the majority of existing studies have significant methodological weaknesses. Also, little is known about the impact of psycho-educational interventions delivered by booklets and in developing countries like Jordan.ObjectiveThe aim of this study was to examine the effectiveness of psycho-education delivered via a printed booklet for PDwS and their PCs’ in Jordan.MethodsA single blind parallel randomized controlled trial was conducted between September 2012 and September 2013 at four mental outpatient clinics in Amman, Jordan. One hundred and twenty-one PDwS with their PCs were allocated randomly to an experimental (psycho-educational intervention plus treatment as usual in outpatient clinic) group (n = 58) or control (treatment as usual alone) group (n = 63). Outcomes, measured prior randomization (pretest), immediately post-intervention (posttest 1) and at three months after intervention (posttest 2).ResultsParticipants receiving psycho-education and treatment as usual had better knowledge of schizophrenia, reduced positive and negative symptoms and hospitalisation at both follow-up points. PCs had reduced burden of care and experienced a better quality of life.ConclusionPsycho-education delivered via printed booklets improves outcomes for PDwS and their PCs in Jordan better than treatment as usual. Our hypothesis is supported.Disclosure of interestThe author has not supplied his declaration of competing interest.


2021 ◽  
Author(s):  
Alireza Rahmani ◽  
Ali Tarighat-Esfanjani ◽  
Bahram Niknafs ◽  
Omid Mohammad Tavakoli-Rouzbehani ◽  
Vahid Maleki

Abstract Background and objectives: The kidney is probably the most crucial target of microvascular damage in diabetes, which can ultimately eventuate end-stage renal disease (ESRD). Hemodialysis is the most usual way of renal replacement therapy in ESRD. Patients receiving hemodialysis are susceptible to many complications like hyperglycemia, inflammation, depression, anxiety, and poor quality of life. So, they constrained to consume many drugs. Medicinal herbs are used in different cultures as a reliable source of natural remedies. This study aims to determine the efficacy of Nigella sativa (NS) oil supplementation on blood glucose, kidney function tests, inflammation, oxidative stress, quality of life, and depression in hemodialysis patients.Methods and analysis: This double-blind, randomized controlled trial will enroll 46 patients with diabetes mellitus who give hemodialysis thrice a week. Patients who have an inflammatory or infectious disease, and who receiving nonsteroidal anti-inflammatory drugs, will be excluded. Patients will be randomized to the treatment and control group, which will be recommended using two soft gel of NS and paraffin oil, respectively. Laboratory tests will be assessed at baseline and end of the study, including fasting blood sugar, glycated albumin, insulin, creatinine, blood urea nitrogen, urea, uric acid, superoxide dismutase, malondialdehyde, total antioxidant capacity, high sensitive C reactive protein, and 24-hour urine volume. Also, the kidney disease and quality of life and hospital anxiety and depression scale questionnaires will be evaluated.Ethics and dissemination: According to our knowledge no sever adverse effect have been reported. The protocol was found to be in accordance to the ethical principles and national norm standard for conducting medical research in Iran (IR.TBZMED.REC.1399.109). Both positive and negative findings will be reported.Trial registration: Iranian registry of clinical trials: IRCT20200411047027N1. Registered on 31 may 2020, https://fa.irct.ir/user/trial/48113/view


Sign in / Sign up

Export Citation Format

Share Document